Vantage Consulting Group’s Kyntra Bio KYNB Stock Holding History

Vantage Consulting Group’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-7,828	Closed	-$60.6K	–	4
2025 Q1	$60.6K	Hold	7,828	–	–	1.21%	4
2024 Q4	$104K	Hold	7,828	–	–	0.99%	5
2024 Q3	$78.2K	Hold	7,828	–	–	0.68%	4
2024 Q2	$175K	Hold	7,828	–	–	0.13%	184
2024 Q1	$460K	Hold	7,828	–	–	0.29%	36
2023 Q4	$173K	Hold	7,828	–	–	0.12%	197
2023 Q3	$169K	Hold	7,828	–	–	0.11%	195
2023 Q2	$528K	Sell	7,828 -3,840	-33%	-$1.59M	0.3%	20
2023 Q1	$5.44M	Sell	11,668 -12,561	-52%	-$6.65M	3.09%	4
2022 Q4	$9.7M	Hold	24,229	–	–	5.73%	3
2022 Q3	$7.88M	Hold	24,229	–	–	4.6%	3
2022 Q2	$6.4M	Buy	24,229 +22	+0.1%	+$5.62K	3.59%	4
2022 Q1	$7.28M	Sell	24,207 -22	-0.1%	-$7.67K	2.84%	4
2021 Q4	$8.54M	Hold	24,229	–	–	2.3%	5
2021 Q3	$6.19M	Hold	24,229	–	–	1.33%	5
2021 Q2	$16.1M	Hold	24,229	–	–	2.81%	4
2021 Q1	$21M	Hold	24,229	–	–	4.22%	3
2020 Q4	$22.5M	Buy	+24,229	New	+$25.5M	1.83%	3

Other funds holding KYNB

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Vantage Consulting Group's KYNB Position: Q2 2025 in Review

Vantage Consulting Group sold out of Kyntra Bio (KYNB) in Q2 2025, closing a stake of 7,828 shares — an estimated $60.6K sold.

Vantage Consulting Group first reported a position in KYNB in Q4 2020 and held it in 18 quarters. The position peaked at $22.5M in Q4 2020. 30 funds tracked by Wall St. Rank hold KYNB as of Q2 2025.

Vantage Consulting Group reported no remaining Kyntra Bio position as of Q2 2025 after selling out during the quarter.
Vantage Consulting Group sold 7,828 Kyntra Bio shares in Q2 2025, an estimated $60.6K.
Vantage Consulting Group first reported a position in Kyntra Bio in Q4 2020 and held it in 18 quarters.
Vantage Consulting Group's Kyntra Bio position peaked at $22.5M in Q4 2020.
30 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2025.

Based on Vantage Consulting Group's 13F filing for Q2 2025, filed 12 Aug 2025.